April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
22 citations
,
March 2019 in “European Journal of Ophthalmology” Preservative-free latanoprost effectively lowers eye pressure with fewer side effects.
January 2025 in “Dermatology Review” Acitretin may cause salivary gland inflammation.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
3 citations
,
September 1998 in “International Journal of Dermatology” Acitretin effectively improved the woman's skin condition.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
October 2023 in “Indian journal of ophthalmology. Case reports” A woman lost vision in one eye after a forehead injection, but prompt treatment led to partial vision recovery.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
20 citations
,
June 2003 in “Neurology” Tacrolimus and corticosteroids can improve symptoms of Satoyoshi syndrome.
13 citations
,
January 2021 in “The American journal of gastroenterology” Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.
January 2008 in “Zhonghua linchuang mianyi he biantai fanying zazhi” The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
2 citations
,
May 2021 in “Neuropathology & applied neurobiology/Neuropathology and applied neurobiology” Correct diagnosis and treatment are crucial for effective management of lipid storage myopathies.
31 citations
,
July 1975 in “PubMed” Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
March 2026 in “International Journal of Pharmaceutics and Drug Analysis” The polyherbal emulgel is a promising treatment for rheumatoid arthritis with effective and sustained results.
3 citations
,
March 2023 in “JAAD case reports” Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.